EpiTan In-Licenses OraDisc A From Access Pharmaceuticals

EpiTan has in-licensed the Australian and New Zealand rights to OraDisc A from Access Pharmaceuticals (Dallas, Texas) as part of its strategy to establish a specialty pharmaceutical business focused on ethical dermatology. OraDisc A, which is clinically-proven to accelerate the healing of mouth ulcers, will be filed with the Therapeutic Goods Administration in the first quarter of calendar 2005 and is expected to be launched in the second quarter of calendar 2006. OraDisc A was approved by the FDA in September 2004 for the treatment of mouth ulcers.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=18976820&full=1)